Trial Profile
A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with moderate to severe atopic dermatitis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2020
Price :
$35
*
At a glance
- Drugs MOR 106 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms IGUANA
- Sponsors Galapagos NV
- 08 Jul 2020 The trial has been completed in Poland according to European Clinical Trials Database record.
- 18 Dec 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Mar 2020.
- 14 Nov 2019 Planned End Date changed from 1 Jun 2020 to 1 Mar 2020.